Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells

STMN1 overexpression correlates with biological behavior in human cutaneous squamous cell carcinoma

“…Numerous studies have noted that the constitutive activation and overexpression of STMN1 were associated with a variety of human malignancies, including acute leukemia [12], nasopharyngeal carcinoma [13], hepatocellular carcinoma [14], gastric cancer [15], cervical carcinoma [16], colorectal cancer [17] and esophageal squamous cell carcinoma [18]. Nie et al [19] found that increased STMN1 expression was observed non-small cell lung cancer, and high expression of STMN1 protein was tightly related to poor tumor differentiation, large tumor size, advanced N stage, and advanced TNM stage, implying STMN1 may play a critical role in the progression of NSCLC and may serve as a useful prognostic biomarker of the patients with NSCLC.…”

BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine

“…For this purpose, the effects of decitabine treatment (1mM or 5mM for 48h) were investigated in U937 cells silenced for BNIP3 or BNIP3L. Gene silencing was performed using lentivirusmediated shRNA, as previously described, 9 and was confirmed by quantitative PCR and western blot. In addition to gene expression, protein levels of BNIP3 and BNIP3L were increased by decitabine (Figure 2C,D).…”

“…OS and EFS were defined as previously described. 8,9 With an average follow-up of 37 months, univariate analysis showed that lower levels of BNIP3L (below the median) negatively impacted OS, along with IPSS and advanced age (all P<0.05). Multivariate analysis showed that lower BNIP3L expression was an independent prognostic factor for worse OS (all P<0.05).…”

Stathmin 1 expression in plasma cell neoplasms

“…Stathmin 1, also named oncoprotein 18 (OP18) or leukemia-associated phosphoprotein p18 (LAP18), is a microtubule destabilizer that plays an important role in cell progression, clonogenicity, differentiation and survival 2 . Stathmin 1 overexpression has been reported in hematological malignancies, including acute myeloid leukemia, acute lymphoid leukemia, lymphoma, high-risk myelodysplastic syndromes and primary myelofibrosis 3, 4, 5, 6, 7. Functional studies indicate that high stathmin 1 expression is able to sustain rapid cell division and proliferation of leukemia cells, which are suppressed by stathmin 1 inhibition 5, 8, 9.…”

“…Stathmin 1 overexpression has been reported in hematological malignancies, including acute myeloid leukemia, acute lymphoid leukemia, lymphoma, high-risk myelodysplastic syndromes and primary myelofibrosis 3, 4, 5, 6, 7. Functional studies indicate that high stathmin 1 expression is able to sustain rapid cell division and proliferation of leukemia cells, which are suppressed by stathmin 1 inhibition 5, 8, 9. Using the microarray approach, stathmin 1 has been identified as one of 15 relevant genes that determine the outcome in MM patients 10 …”